ストックスクリーナーアプリを入手
10.42
3.07%
0.31
プレマーケット:
10.42
前日終値:
$10.11
開ける：
$10.29
24時間の取引高:
1.39M
Relative Volume:
0.69
時価総額：
$1.44B
収益：
$62.04M
当期純損益:
$-533.34M
株価収益率:
-2.6582
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
+1.91%
1か月 パフォーマンス:
+41.96%
6か月 パフォーマンス:
+3.89%
1年 パフォーマンス:
+9.80%
1日の値動き範囲:
$10.01
$10.58
1週間の範囲:
$9.92
$11.24
52週間の値動き範囲:
$6.56
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
VIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.42 | 1.44B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology Phase 1 Data on Dual-Masked T-Cell Engagers (TCEs) – Market - HPBL
Vir Biotechnology Inc. (VIR) Stock Overview and Recent Developments – Market - HPBL
Vir Biotechnology Shares Surge After Opening Higher: A Market Overview – Market - HPBL
What is Leerink Partnrs’ Forecast for VIR Q1 Earnings? - Defense World
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) PT at $34.83 - Defense World
Vir Biotechnology (NASDAQ:VIR) Shares Down 10.4%Here's What Happened - MarketBeat
Q1 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
JPMorgan Chase & Co. Has $8.14 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Q2 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $34.83 - MarketBeat
Leerink Partners Boosts Vir Biotechnology (NASDAQ:VIR) Price Target to $20.00 - MarketBeat
Nordea Investment Management AB Sells 286,600 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 - MSN
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment - MSN
Morgan Stanley Doubles Vir Biotechnology Price ForecastHere's Why - AOL
Vir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC Wainwright - MarketBeat
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates - MSN
Morgan Stanley Upgrades Vir Biotechnology (VIR) - MSN
Vir Biotech upgraded at Morgan Stanley on cancer drug data - MSN
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58% - GuruFocus.com
Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong? (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology (NASDAQ:VIR) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 By Investing.com - Investing.com Canada
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies - Yahoo Finance
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology S - GuruFocus.com
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology Stock - Yahoo Finance
Vir Biotechnology stock soars 58%: Is it still a buy? - Dataconomy
Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week HighHere's Why - MarketBeat
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment - MSN
Vir Biotechnology director Vicki L. Sato sells $137,219 in stock - Investing.com India
JPMorgan raises Vir Biotechnology stock target to $14 By Investing.com - Investing.com Canada
Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN
Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 10,960 Shares of Stock - MarketBeat
Vir Biotechnology director Vicki L. Sato sells $137,219 in stock By Investing.com - Investing.com UK
Vir Scores In Oncology Pivot With Strong Early T-Cell Engager Results - Citeline News & Insights
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer - MSN
Top Midday Gainers - Marketscreener.com
Vir Biotechnology stock hits 52-week high of $13.18 By Investing.com - Investing.com Canada
Vir Biotechnology, Inc. (NASDAQ: VIR) Stock Surges 29% on Promising Cancer Treatment Data - HPBL
Vir Biotechnology Stock Soars On Prostate Cancer Trial DataHere's Why - Benzinga
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpHere's Why - MarketBeat
Investors Purchase High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):